Back

Effect of sacubitril/valsartan on cognitive function in patients with HFpEF: A prespecified analysis of PARAGON-HF

29 August 2020 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Mechanisms of Heart Failure and Implications for Clinical Translation Heart Failure with Preserved Ejection Fraction (HFpEF) ESC Premium Access ESC Congress 2020

About the speaker

Photo
Doctor Pooja Dewan

Chelsea and Westminster Hospital NHS Foundation Trust, London (United Kingdom of Great Britain & Northern Ireland)

7 More presentations in this session

Presentation thumbnail
Diagnostic usefulness of passive leg raising test for detection of heart failure with preserved ejection fraction compared to cycle ergometer exercise(invasive hemodynamic study)
Associate Professor S. Hwang (Incheon, KR)
Abstract Slides Video
Presentation thumbnail
Impact of catheter ablation on HFpEF in people with comorbid atrial fibrillation and HFpEF using invasive haemodynamic testing.
Doctor H. Sugumar (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
Characterization of myocardial sodium-glucose cotransporter 1 expression in humans with heart failure and reduced ejection fraction
Doctor A. Sayour (Budapest, HU)
Abstract Slides Video
Presentation thumbnail
Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF
Doctor S. Kristensen (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Sex-specific effect of obesity on exercise capacity and diastolic function
Doctor M. Jung (Seoul, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Mechanisms of Heart Failure and Implications for Clinical Translation

The Event

Event poster

ESC Congress 2020

29 August - 1 September 2020
You may be interested in
thumbnail
Congress Presentation
Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.
thumbnail
Congress Presentation
Pharmacotherapy in HFpEF: where do cardiometabolic drugs fit in?
thumbnail
Congress Session
Clinical phenotypes of heart failure with preserved ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources